COGT logo

COGT
Cogent Biosciences Inc

3,184
Mkt Cap
$6.25B
Volume
8.62M
52W High
$43.73
52W Low
$3.72
PE Ratio
-13.77
COGT Fundamentals
Price
$35.24
Prev Close
$38.49
Open
$37.67
50D MA
$37.02
Beta
1.58
Avg. Volume
2.2M
EPS (Annual)
-$2.55
P/B
10.38
Rev/Employee
$0.00
$4,008.57
Loading...
Loading...
News
all
press releases
Cogent Biosciences (NASDAQ:COGT) Stock Price Down 10.2% - Should You Sell?
Cogent Biosciences (NASDAQ:COGT) Shares Down 10.2% - Time to Sell...
MarketBeat·9h ago
News Placeholder
More News
News Placeholder
Biotech Stocks To Consider - April 1st
Moderna, Danaher, and Cogent Biosciences are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies that use biological science...
MarketBeat·10h ago
News Placeholder
Cogent Biosciences Stock Falls 6% After Submission Of New Drug Application For Bezuclastinib
(RTTNews) - Stock of Cogent Biosciences, Inc. (COGT) is falling about 6 percent on Wednesday morning trading after the submission of its New Drug Application to the U.S. Food and Drug Administration for bezuclastinib in patients with Gastrointestinal Stromal Tumors...
Nasdaq News: Markets·12h ago
News Placeholder
Hennion & Walsh Asset Management Inc. Buys 37,938 Shares of Cogent Biosciences, Inc. $COGT
Hennion & Walsh Asset Management Inc. increased its position in Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 12.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 338,065 shares of the technology c...
MarketBeat·3d ago
News Placeholder
Assenagon Asset Management S.A. Trims Stock Holdings in Cogent Biosciences, Inc. $COGT
Assenagon Asset Management S.A. cut its holdings in Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 34.9% in the 4th quarter, according to the company in its most recent filing with the...
MarketBeat·5d ago
News Placeholder
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch
Key PointsRTW Investments added 4,124,755 Cogent Biosciences shares in the fourth quarter; the estimated trade size was $115.95 million...
Nasdaq News: Markets·11d ago
News Placeholder
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding
Key PointsKynam Capital sold 1,720,949 shares of Cogent Biosciences in the fourth quarter; the estimated transaction value was $48.38 million...
Nasdaq News: Markets·11d ago
News Placeholder
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026
Key PointsBoone Capital Management sold 945,042 shares of Cogent Biosciences in the fourth quarter...
Nasdaq News: Markets·12d ago
News Placeholder
HC Wainwright Analysts Lift Earnings Estimates for COGT
Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - HC Wainwright lifted their Q1 2026 EPS estimates for shares of Cogent Biosciences in a research note issued on Tuesday, March 17th. HC Wainwright analyst R. Burns now forecasts that the technology company will post earnings of ($0.53) per share...
MarketBeat·14d ago
News Placeholder
COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM
Cogent Biosciences jumps after FDA accepts bezuclastinib NDA for treating non-advanced SM, with a decision due by Dec. 30, 2026.
Zacks·15d ago
<
1
2
...
>

Latest COGT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.